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Abstract: 
Mycoplasma pneumoniae ​is a high-burden pathogen which causes mild to significant 
infections of the respiratory system. According to the CDC, an estimated two million cases occur 
yearly in the United States alone, demonstrating the widespread effect of the pathogen. In 
addition to being the cause of respiratory infections, ​M. pneumoniae ​has also been implicated in 
exacerbating pre-existing asthma conditions. These morbidities make finding a vaccine candidate 
a vital part of easing the healthcare burden caused by the pathogen. The current mechanism of 
infection is unknown, but recent evidence points to the Community Acquired Respiratory 
Distress Syndrome (CARDS) toxin as being involved in that mechanism. We believe that if a 
mutant was created that is a knockout for the CARDS toxin, then the virulence will be 
diminished. This will provide further evidence to the theory that the CARDS toxin is responsible 
for the pathogenesis of the bacteria. In this experiment, we isolated a ​M. pneumoniae​ mutant and 
placed it in a mouse model to test for virulence. After using transposon insertion to find a 
possible mutant, polymerase chain reaction (PCR) was run to confirm the insertion of the 
transposon. The mutant was then placed in a mouse model to compare its virulence with that of 
wild-type ​M. pneumoniae​. When placed in the model, the mutant ​M. pneumoniae​-infected mice 
had lower lesion scoring and lower bacterial counts in serial dilutions than those of the wild-type 
M. pneumoniae. ​This gave proof that the isolated mutant was in fact attenuated for virulence. 
Further steps must be taken to ascertain the identity of the mutant, such as DNA sequencing and 
in vitro studies. Given the results, this experiment was a success in isolating a virulence- 
attenuated ​M. pneumoniae​ mutant, and is a step closer to finding a possible vaccine for the 
disease. 
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Introduction: 
Mycoplasma pneumoniae ​is a small atypical bacteria known for its ability to cause 
significant respiratory tract infections in humans worldwide. They are well-documented for 
causing upper and lower respiratory infections. It is widespread in Africa, North America, and 
Europe, but data suggests the pathogen is endemic all over the world. Past research proved ​M. 
pneumoniae ​has the ability to exacerbate pre-existing asthma conditions in patients already 
suffering from airway irritation (Atkinson ​et al., ​2008). The current hypothesis states that the 
Community-Acquired Respiratory Distress Syndrome (CARDS) toxin may be a contributing 
factor to the virulence of the pathogen. If the genome of ​M. pneumoniae​ can be mutated to 
disrupt the CARDS toxin, then the virulence of the pathogen should be reduced. In this paper, a 
mutant form of ​M. pneumoniae ​was isolated, in the hopes of finding the desired attenuation. 
The infection caused by the bacteria ​M. pneumoniae ​is a significant burden on healthcare 
systems worldwide. Climate and weather are not thought to significantly affect the spread of the 
pathogen (Atkinson ​et al., ​2008). It has a long incubation period and low transmission rate, and 
can survive in respiratory tracts for long periods of time (Atkinson ​et al., ​2008). It can manifest 
in several pathologies, ranging from milder upper respiratory infections to much more severe 
cases of community-acquired pneumonia (Kashyap ​et al., ​2010). Typically, the final stage of the 
disease results in community-acquired pneumonia, but up to 20% of patients can be 
asymptomatic (Atkinson ​et al., ​2008). The global burden of the pathogen can be seen in ​Fig. 1 
(Parrott ​et al., ​2016). 
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Figure 1 (adapted from Parrott ​et al., ​2016):​ ​This image shows the number of ​M. pneumoniae 
cases worldwide from 2000-2012. Russia, China, and Brazil have high numbers of cases as 
evidenced by the key on the right of the image. 
Fig. 1​ shows how prevalent the infections caused by ​M. pneumoniae ​are globally. Work on 
finding a vaccine candidate has been stymied by the need to elucidate the disease mechanism. 
Beyond respiratory illnesses, this pathogen has also been linked to exacerbating chronic asthma 
symptoms (Sutherland ​et al., ​2004). Much work has been done on finding the mechanism of 
virulence of ​M. pneumoniae​. Finding the right mechanism can lead to finding a possible vaccine. 
M. pneumoniae ​are atypical bacteria with an extremely small genome. They are among 
the smallest bacterial organisms, with a one to two micrometer-long spindle shape (Atkinson ​et 
al., ​2008). Their genome is 600 to 1,350 kbp long (He ​et al., ​2016). The pathogen is not only 
found in humans, but is known to infect insects, animals, and plants. ​M. pneumoniae ​causes 
disease by interacting with the host’s epithelial tissue. It survives by adhering to the respiratory 
epithelium, where it is protected from the mucus in the nose and throat via its adhesive properties 
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(Kashyap ​et al.​, 2010). The damage it causes through adhesion is extensive. Several proteins 
such as P1, P40, and P90 come together to form an adhesion protein complex. This complex 
allows ​M. pnuemoniae ​to anchor itself onto cellular membranes (He ​et al., ​2016). Through this 
adherence process, ​M. pneumoniae ​causes the trademark symptoms often seen in patients. 
Through the process of cytoadherence, ​M. pneumoniae ​produces hydrogen peroxide, 
superoxide radicals, and induces the formation of endogenous toxic oxygen molecules (Waites ​et 
al., ​2004). These compounds cause severe distress to the respiratory lining where the bacteria 
adheres to, and causes the characteristic cough experienced by patients. In the lower respiratory 
airway pathways, ​M. pneumoniae ​may be opsonized and taken up by macrophages. The 
activation of immune responses will result in the production of TNF-alpha, IFN-gamma, and 
various interleukins (Waites ​et al., ​2004). It has been speculated that the release of 
proinflammatory cytokines during a ​M. pneumoniae ​infection is related to the exacerbation of 
pre-existing chronic conditions such as bronchial asthma in the host (Waites ​et al., ​2004). 
Several studies in the past have been done to ascertain the link between ​M. pneumoniae 
and chronic lung diseases such as asthma. A 1970 study found that 32% of asthma patients 
involved in the research showed evidence for infection by either ​M. pnuemoniae ​or another 
respiratory virus (Berkovich ​et al., ​1970). Another study conducted further analysis, and found 
that 19% of asthma patients had mycoplasma or viral infections after severe asthmatic episodes 
(Huhti ​et al., ​1974). Further research has drawn even more correlation; a 2004 study found 20% 
of patients with previously diagnosed asthma faced exacerbated asthmatic conditions when a ​M. 
pneumoniae ​infection occurred (Biscardi ​et al., ​2004). In 2009, Varshney ​et al.,​ in a study 
conducted among Indian children with asthma, found ​M. pneumoniae ​antibodies in 22% of those 
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who reported moderate to severe asthma symptoms (Varshney ​et al.,​ 2009). In a similar study, 
IgM antibodies against ​M. pneumoniae ​were found in 24% of children presenting with 
respiratory infections (Shenoy ​et al.,​ 2005). Asthma symptoms were found to be exacerbated in 
another study, after an infection by ​M. pneumoniae ​(Yeh ​et al.,​ 2016). PCRs were used to 
determine the presence of ​M. pneumoniae ​in pulmonary airways of adult chronic asthma 
patients. 45% of the patients tested had ​M. pneumoniae ​in their respiratory tracts (Kraft ​et al., 
1998). These results were corroborated by findings which showed the presence of ​M. 
pneumoniae-​specific IgM antibodies in patients who presented with exacerbated asthma 
conditions (Seggev ​et al., ​1986). Clearly, there is an association between the respiratory viral 
infections and the presence of ​M. pneumoniae ​within the respiratory tract. However, the exact 
molecular mechanism of action has yet to be elucidated. 
Much work has been done to find out what the exact mechanism that underlies ​M. 
pneumoniae-​induced infection. One possible mechanism is the Community Acquired Respiratory 
Distress Syndrome toxin, or the CARDS toxin. The CARDS toxin was recently characterized as 
a possible mechanism used by ​M. pneumoniae ​in its cytoadherence function. The toxin is 
encoded by the mpn372 gene in the pathogen genome (Kannan ​et al., ​2010). CARDS is an 
exotoxin that binds to surfactant protein A, allowing it to become internalized by cells. (Kannan 
et al.,​ 2010). This virulence factor is known for its ADP-ribosylating and vacuolating abilities 
(Becker ​et al., ​2015). This toxin is made up of three domains which form its tertiary structure, 
which can be seen in ​Fig. 2​. Domain 1 is associated with ADP-ribosylating activity. Domains 2 
and 3 are more linked in function, and are associated with the vacuolating ability of the toxin 
(Becker ​et al., ​2015). 
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Figure 2 (adapted from Becker et al., 2015): ​This image shows the tertiary structure of 
the CARDS toxin. The three domains are highlighted in different colors. 
The exact arrangement of the domains can be seen more clearly in​ Fig. 3​. This image shows how 
the domains are arranged in the gene, and what purposes each one serves. 
  
Figure 3:​ ​This image shows the three domains of the CARDS toxin, as well as the linker. 
When it was purified, the toxin was able to cause significant dose-dependent cytopathology in 
mammalian cell and organ cultures. These researchers showed that an exposure to the purified 
recombinant CARDS toxin presented pathological signs that were similar to an infection by ​M. 
pneumoniae. ​This provided evidence that the toxin is related to the pathologic effects seen during 
an infection (Kannan ​et al., ​2010). 
Further research was conducted on the role of the CARDS toxin in ​M. pneumoniae 
infection. One such study was conducted using recombinant-CARDS toxin in naive mice 
(Medina ​et al., ​2012). When the mice were exposed to the rCARDS toxin, mucus expression was 
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heightened, and the major mucin gene Muc5AC was expressed at greater levels (Medina ​et al., 
2012). The increased production of mucus is an indicator of both ​M. pneumoniae ​infection and 
allergic lung inflammation (Chu ​et al., ​2005). An image (​Fig. 4)​ taken from this paper is shown 
below to highlight the increased mucus production on lung slides (Medina ​et al., ​2012). 
 
Figure 4 (adapted from Medina et al., 2012):​ Slide A shows pathology of a lung section from a 
mouse treated with carrier fluid and stained with PAS stain. Slide B shows lung pathology taken 
from a mouse treated with rCARDS toxin, and stained with PAS. The arrow indicates the 
buildup of mucus production in the rCARDS-treated animal. 
In addition to the increased mucus production, the researchers also witnessed an inflammation of 
eosinophilic-lymphocytic composition. Bronchoalveolar lavage fluid (BALF) is a prime 
indicator of immune responses in the lungs. Fluid was pumped through the trachea into the 
lungs, and then withdrawn with a syringe to obtain BALF (Hardy ​et al., ​2009). This fluid 
contained cells found in the lungs. These cells are washed and counted to enumerate the amount 
of immune cells found in the lungs. The rCARDS toxin-treated mice had higher counts of 
neutrophils, eosinophils, lymphocytes, and macrophages by day 7 post infection (Medina ​et al., 
2012). In addition to the higher immune responses, rCARDS toxin-treated mice also had higher 
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lesion scoring in lung sections. These inflammatory and immunologic effects gave evidence that 
the CARDS toxin is important to the disease-causing ability of ​M. pneumoniae. ​Based on this 
data, a hypothesis was formed for this project. 
In this thesis, a mutant form of ​Mycoplasma pneumoniae ​was created and tested in a 
mouse model to assess its effects on disease virulence. The goal was to create a mutant which 
was a CARDS toxin-knockout, and demonstrated a lower virulence when compared to the 
wild-type pathogen. This would provide further evidence that the CARDS toxin is an important 
component in the disease-causing ability of ​M. pneumoniae.  
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Methods: 
Creation of a CARDS-attenuated mutant ​Mycoplasma pneumoniae. ​Previous work in our lab 
resulted in the creation of a transposon-mutant library for ​M. pneumoniae ​(Szczepanek ​et al., 
2010)​.​ This library contains 1658 mutants, and given that ​M. pneumoniae​ has roughly 690 
protein-encoding genes, the library provides roughly ~2.5x coverage per gene. 
To create the CARDS-toxin knockout mutant, a transposon was inserted into a binding 
region in domain 1 of the gene (mpn372). Domain 1 is an ADP-ribosylating region, and the 
arrangement of the full CARDS toxin gene can be seen in ​Fig.3.​ The desired insertion point of 
the transposon can be seen in ​Fig. 5.​ Using the pMT85 plasmid, the transposon will be inserted 
into this region (Janis ​et al., ​2008). The amplicon size was estimated to be 1821 base pairs long. 
Gentamicin and kanamycin were inserted along with the plasmid to ensure proper plasmid 
insertion. 
 
Figure 5:​ ​The domain arrangement of mpn372, and the desired insertion point of the transposon. 
 
Given that the mutant library was generated via “haystack mutagenesis,” the transposon 
insertions are random, requiring PCR screening to identify transposon insertions and putative 
mutants. This technique was used to screen for transposons which disrupted the promoter region. 
Insertions in this region are more likely to result in absolute gene knockouts, but insertions in the 
full open reading frame were also considered. We designed CARDS-specific primers with the 
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forward primer sitting upstream of the transcriptional start site. The primers consisted of 2 
groups which run in opposite directions. Group 1 consisted of primers running in the reverse 
direction of the CARDS toxin (5’ → 3’) and primers running in the reverse direction of the 
transposon (3’ → 5’). Group 2 was the same but vice versa; it consisted of primers running in the 
reverse direction of the CARDS toxin (3’ → 5’) and the forward direction of the transposon (5’ 
→ 3’). These combinations of primers showed whether the transposon is properly inserted into 
domain 1 at the binding region. Several different primers were run with both the wild-type and 
mutant ​M. pneumoniae ​DNA to confirm which primers work best without spurious 
amplification, and to find the best screening primer pairs. 
After finding primers that resulted in the least spurious amplification, they were run 
through a temperature gradient to optimize the annealing temperature. Other PCR conditions 
were fine-tuned to reduce spurious amplification in the selected pair. These conditions included 
determining cycle time and number.  
Because the mutant library is extensive, pooling was used to screen large numbers of 
mutants for an insertion in the CARDS gene. 30 mutants were pooled together, and a PCR was 
run on each pool. Individual screening was conducted on the pool with the best insertion, and the 
mutant with the best transposon insertion in that pool was grown in cell culture. This mutant was 
harvested and run in a PCR to assess where the transposon was inserted and whether it was 
attenuated.  
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Assessment of mutant virulence compared to wild-type virulence in a mouse model. ​After 
the mutant was grown and checked for genomic attenuation, it was tested in an animal model to 
assess virulence attenuation. BALB/c mice procured from Jackson Laboratory were used as the 
animal study. 2 groups of mice, each containing 10 8-week old female mice, were set up for the 
experimental protocol.  Mice were housed at 5 mice/cage, with 2 cages per experimental group. 
Group 1 received 5x10^7 CFU of wild-type ​Mycoplasma pneumoniae ​strain PI128 on D0 
intranasally. Group 2 received 5x10^7 CFU of the mutant strain intranasally on D0 as well. 4 
days post infection, the mice were sacrificed. Carbon monoxide cannot be used to sacrifice these 
animals as the compound may interfere with bacterial recovery later. Instead, the mice were 
anesthetized with isoflurane and cervical dislocation was used to euthanize the animal. A paw 
pinch was used as a confirmation of death. ​Fig. 6​ shows the timeline of events during animal 
trials. 
 
Figure 6:​ ​A brief timeline showing the steps taken during animal trials. 
Once death has been confirmed, the mice were dissected following previously 
characterized protocols (Morton ​et al., ​2017). Portions of the lower right lobe of the lung were 
harvested and stored in complete Fortified Commercial Medium in order to perform bacterial 
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recovery, and the rest of the lung was fixed in 10% neutral buffered formalin. The resected tissue 
was used for both histopathology and bacterial recoveries. Bacterial recoveries were performed 
by placing the resected lower right lung in 3 mL of FC, followed by two minutes of steady 
vortexing. The tissue sample was then incubated for 3 hours, filtered, and used to perform serial 
10-fold dilutions. This gave CCU counts for the mutant and WT pathogens. The histopathology 
obtained from the samples was used for lesion scoring. Lesions were graded on a scale of 0 to 4, 
with 0 having no visible lesions and 4 having severe lesions, in increments of 1. These scores 
were assigned in blinded fashion by an experienced individual trained by a board certified 
veterinary pathologist (Szczepanek ​et al., ​2012). 
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Results: 
Isolation of mutant P563. ​When the mutant library pools were run together, pool 19 showed a 
possible mutant with a good insertion of the transposon. This specific pool can be seen in ​Fig. 7, 
with pool 19 indicated. 
 
Figure 7: ​An example of some of the PCR pooling done to find a putative mutant. Pool 19, 
indicated by the red circle, showed a mutant with good insertion of the transposon. 
When this pool was run individually, with each mutant in different lanes, mutant P563 showed 
good disruption of the binding region. A PCR was run on this mutant in the presence of the 
primers to see which primer combination gave the best disrupting insertion of the transposon. 
The results of that PCR can be seen in ​Fig. 8. 
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Figure 8:​ ​PCR of mutant P563 in presence of several different primers. Non-A represents 
non-adherent (floating) cells and A represents adherent cells. 
Lane 1 contains a ladder. Lanes 2 and 3 contain a forward CARDS toxin primer and reverse 
transposon primer. Lanes 3 and 4 contain a reverse CARDS toxin primer and forward transposon 
primer. Adherent and non-adherent cells were run together, but no significant differences were 
observed between the two. The adherent cells were used to grow the mutant and infect the mice. 
Lanes 2-4 gave us fragment sizes that allowed us to map the insertion based on the sequence. 
Fragment sizes are indicated on the left of the gel in Fig. 7. Lanes 2 and 3 had fragment sizes of 
850 bp and 1650 bp. Lanes 3 and 4 had fragment sizes of 1000 bp and 2000 bp. By knowing the 
fragment sizes from the PCR screening, sequencing can be used to map the insertion in the gene.  
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Attenuation of virulence in the mouse model. ​Lesion scoring of the animal lungs showed the 
mice dosed with mutant attenuated ​M. pneumoniae ​had lower scoring when compared to the WT 
PI428 strain ​M. pnuemoniae. ​The average scoring for the mutant strain was 1.0, while the 
average score for the WT strain was 1.5. This means the mutant strain had less lesion severity in 
the lungs, with less scarring being noted. The WT strain had more severe lesions, hence the 
higher scoring for the animal.​ Fig. 9​ shows the graph of the comparison between the two strains 
in lesion scoring. 
 
Figure 9:​ ​WT PI428 strain and P563 strain lesion scoring (0 to 4). Significance was noted here 
(p < 0.05). 
Lesions were less severe in the P563-inoculated mice, as evidenced by the lower lesion count in 
those animals. This gives evidence that the P563 mutant was attenuated for virulence. In addition 
to the lesion scoring, bacterial recoveries were conducted to assess color-changing units (CCUs) 
via serial dilutions. The results of this experiment can be seen in ​Fig. 10. 
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Figure 10:​ ​CCU counts from serial dilutions conducted on bacterial recoveries. Recoveries were 
taken from lower right lung tissue. Significance was noted here (p < 0.05). 
The recoveries show that P563 had an average cell count of 10^1 CCU. In comparison, the WT 
strain PI1428 had an average count of 10^2 CCU. The highest value from the P563 recovery was 
10^2 CCU, compared to 10^3 CCU from the same value for PI1428. The attenuated P563 was 
not able to grow and infect the host cells as much as the WT PI1428, giving further evidence to 
the virulence attenuation. 
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Discussion: 
The burden ​Mycoplasma pneumoniae ​places on healthcare systems worldwide is 
significant. It causes high numbers of pneumonia and asthmatic cases in patients each year. 
Because of its effects, elucidating the mechanism of action of its infection is of great importance. 
As mentioned before, there is evidence linking the CARDS toxin and the primary virulence of 
M. pneumoniae. ​The goal of this project was to create an attenuated mutant with demonstrated 
reduced virulence. The lesion scoring from the ​in vivo ​testing showed significant reduction in 
virulence in the P563 mutant. The bacterial recoveries also showed less bacteria per milliliter 
when compared to the recoveries of the WT strain. This data, when taken together, shows that 
the mutant did have attenuated virulence. 
There are several steps to take with the conclusions from this project. While the mutant 
was confirmed to have attenuated virulence, it still needs to be sequenced to determine if the 
transposon is properly inserted in the binding region in domain 1, disrupting the gene. The PCR 
results gave evidence that the transposon was able to insert properly. However, DNA sequencing 
is required to map the proper insertion, before this mutant can be used in further study. 
In addition to DNA sequencing, ​in vitro ​studies should be conducted on the mutant. 
These studies will be used to phenotype the mutant. While we know the mutant is not as virulent 
as the WT pathogen, we still need to confirm this decrease in virulence is due to the disruption of 
the CARDS toxin. The CARDS toxin, as demonstrated by the domain layout, is capable of 
ADP-ribosylating, binding, and vacuolating functions. Assays can be designed to assess the 
ADP-ribosylating activity of the toxin. Cytotoxicity assays can also be used to determine the 
function of CARDS in the mutant. An important example of such an assay is determining 
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vacuolation in MRC-5 human lung cells (Kannan ​et al., ​2014). One of the CARDS toxin chief 
functions is its ability to form vacuoles in cells it infects. These vacuoles can be seen under 
microscopy. If the CARDS toxin is disrupted in our mutant, then its ability to form vacuoles will 
also be disrupted. These phenotypic characterizations will aid in determining if the mutant is 
actually a CARDS-toxin knockout.  
As mentioned previously, isolating a CARDS-attenuated mutant of ​Mycoplasma 
pneumoniae ​is key in characterizing the pathogenesis of the disease. If a link between the 
CARDS toxin and virulence can be established, then a step is taken towards finding the 
mechanism of action of the pathogen. The mutant isolated in this study can play a central role in 
finding that link.  
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